Literature DB >> 2323842

Risk factors for male breast cancer: a Franco-Swiss case-control study.

M H Lenfant-Pejovic1, N Mlika-Cabanne, C Bouchardy, A Auquier.   

Abstract

In order to evaluate risk factors in male breast cancer, a case-control study of 91 histologically diagnosed cases and 255 cancer controls, matched for age and year of diagnosis, was conducted in Villejuif (France) and Geneva (Switzerland). Factors studied included marital history, occupational exposure, associated diseases, family history of breast cancer, history of radiation exposure and drugs which increase or are suspected of increasing prolactin or estrogen levels. Cases were significantly more likely to be bachelors or to work as butchers than were the controls. Other statistically significant risk factors identified were family history of breast cancer and therapeutic use of digitalis. Elevated risks, although not significant, were observed for individuals with a past history of tuberculosis, hyperthyroidism, liver cirrhosis or gallstone, who had been treated with isoniazid, or who had worked in high environmental temperatures. Further studies are needed to confirm our results particularly as regards hormonal imbalance and genetic factors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2323842     DOI: 10.1002/ijc.2910450415

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Case-control study of occupational exposures and male breast cancer.

Authors:  P Cocco; L Figgs; M Dosemeci; R Hayes; M S Linet; A W Hsing
Journal:  Occup Environ Med       Date:  1998-09       Impact factor: 4.402

Review 2.  The Epidemiology of Male Breast Cancer.

Authors:  Raina M Ferzoco; Kathryn J Ruddy
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.075

3.  Bilateral Nonsynchronous Male Breast Cancer: Two Case Reports.

Authors:  Yoshiya Horimoto; Mako Hino; Mitsue Saito; Atsushi Arakawa; Toshiharu Matsumoto; Fujio Kasumi
Journal:  Breast Care (Basel)       Date:  2008-02-22       Impact factor: 2.860

4.  Occupation and occupational exposure to endocrine disrupting chemicals in male breast cancer: a case-control study in Europe.

Authors:  Sara Villeneuve; Diane Cyr; Elsebeth Lynge; Laurent Orsi; Svend Sabroe; Franco Merletti; Giuseppe Gorini; Maria Morales-Suarez-Varela; Wolfgang Ahrens; Cornelia Baumgardt-Elms; Linda Kaerlev; Mikael Eriksson; Lennart Hardell; Joëlle Févotte; Pascal Guénel
Journal:  Occup Environ Med       Date:  2010-08-25       Impact factor: 4.402

5.  Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis.

Authors:  Thomas P Ahern; Rulla M Tamimi; Bernard A Rosner; Susan E Hankinson
Journal:  Breast Cancer Res Treat       Date:  2014-02-28       Impact factor: 4.872

Review 6.  HER2-positive male breast cancer: an update.

Authors:  Laura Ottini; Carlo Capalbo; Piera Rizzolo; Valentina Silvestri; Giuseppe Bronte; Sergio Rizzo; Antonio Russo
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-10-04

7.  Prospective evaluation of risk factors for male breast cancer.

Authors:  Louise A Brinton; Douglas A Richesson; Gretchen L Gierach; James V Lacey; Yikyung Park; Albert R Hollenbeck; Arthur Schatzkin
Journal:  J Natl Cancer Inst       Date:  2008-10-07       Impact factor: 13.506

Review 8.  Lobular carcinoma of the male breast associated with the use of cimetidine.

Authors:  P San Miguel; M Sancho; J L Enriquez; J Fernandez; F Gonzalez-Palacios
Journal:  Virchows Arch       Date:  1997-03       Impact factor: 4.064

9.  Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database.

Authors:  Louise A Brinton; J Daniel Carreon; Gretchen L Gierach; Katherine A McGlynn; Gloria Gridley
Journal:  Breast Cancer Res Treat       Date:  2009-03-29       Impact factor: 4.872

10.  Clinicopathological study of male breast carcinoma: 24 years of experience.

Authors:  Parveen Shah; Irfan Robbani; Omar Shah
Journal:  Ann Saudi Med       Date:  2009 Jul-Aug       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.